Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of ES16001 in Patients With COVID-19: a Phase II/III, Multinational, Randomized, Parallel-group, Double-blind, Placebo-controlled Study

NCT05525182 is registered in ClinicalTrials.gov with Genencell Co. Ltd. as lead sponsor.

NCT NCT05525182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05525182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of ES16001 in Patients With COVID-19: a Phase II/III, Multinational, Randomized, Parallel-group, Double-blind, Placebo-controlled Study
Lead sponsor
Genencell Co. Ltd.
Phase
Phase 2/3
Overall status
Unknown status
Start date
July 5, 2021
Completion date
December 31, 2023
Enrollment
706 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19